Back to news archive
Image for New publication on rapid AST platform
News 2020-02-26

New publication on rapid AST platform

The fluidic chip developed by Gradientech and Uppsala University can determine bacterial susceptibility to multiple antibiotics within 2-4 hours. The technology has the potential to allow for faster initiation of targeted treatment for sepsis patients.

The results serve as a proof-of-concept for the commercial QuickMIC® AST system that Gradientech is currently developing.

Link to press-release

Gradientech is an ISO13485 certified company since 2017


Gradientech AB
Uppsala Science Park
SE-751 83 Uppsala

About Gradientech

Gradientech develops, manufactures and sells innovative microfluidic products for high-quality analysis of the behavior of cells and organisms in response to gradients of biomolecules. Our aim is to pioneer life science and healthcare.

Copyright © 2023 Gradientech. All rights reserved. Gradientech, QuickMIC and CellDirector are registered trademarks or trademarks of Gradientech AB.

Next-generation antimicrobial susceptibility testing

Take a look at our E-book